ArticleBlood advances2026
Estimated glomerular filtration rate discordance and cardiopulmonary morbidity in sickle cell disease.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
abstractDiscordance between cystatin C-based and creatinine-based estimated glomerular filtration rate (eGFR) is a recognized cardiovascular risk marker, but its magnitude and clinical significance in sickle cell disease (SCD) remain unknown. We conducted a cross-sectional study of 1099 Black adults (223 with SCD and 876 without SCD) to evaluate eGFR discordance, defined as the percentage difference between cystatin C and creatinine eGFR. Using propensity score overlap weighting to balance covariates, we assessed the association of SCD with continuous discordance and high-risk discordance (cystatin C eGFR ≥30% lower than creatinine eGFR). After overlap weighting, SCD was associated with a profoundly more negative eGFR discordance (adjusted median difference, -14.20%; 95% confidence interval [CI], -19.30 to -9.09) and increased odds of high-risk discordance (adjusted odds ratio [aOR], 1.88; 95% CI, 1.12-3.16) compared with controls. Within the SCD cohort, high-risk discordance was independently associated with prevalent heart failure (aOR, 4.65; 95% CI, 1.91-11.30) and pulmonary hypertension (aOR, 2.70; 95% CI, 1.19-6.17). In multivariable models, heart failure was the dominant independent correlate of more negative discordance, whereas higher hemoglobin was associated with less negative discordance, suggesting a hemolysis-driven mechanism. In trend analyses, eGFR discordance became progressively more negative with declining creatinine eGFR, then appeared to reverse at advanced renal impairment, a pattern absent in non-SCD controls. These findings show that eGFR discordance is disproportionately amplified in SCD and support the evaluation of eGFR discordance as a noninvasive biomarker of nonatherosclerotic cardiopulmonary risk in prospective SCD studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.